First Trust NYSE Arca Biotechnology Index Fund
130 hedge funds and large institutions have $497M invested in First Trust NYSE Arca Biotechnology Index Fund in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 16 closing their positions.
366% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $698K
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
12% more funds holding
Funds holding: 116 → 130 (+14)
11% more capital invested
Capital invested by funds: $447M → $497M (+$50M)
2.13% more ownership
Funds ownership: 38.77% → 40.9% (+2.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Churchill Management
Los Angeles,
California
|
+$33.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$14M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$9.42M |
| 4 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
+$4.23M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$10.7M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.08M |
| 3 |
Nomura Asset Management
Tokyo,
Japan
|
-$2.56M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.46M |
| 5 |
LPL Financial
San Diego,
California
|
-$725K |
FBT Hedge Fund Activity: Q4 2017 in Review
130 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q4 2017, worth a combined $497M — up 11% from $447M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new FBT positions and 16 closed out — a net gain of 14 holders — while 39 added to existing stakes and 32 trimmed.
The largest buyer was Churchill Management, adding an estimated $33.2M. The largest seller was Morgan Stanley, cutting an estimated $10.7M.
- 130 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q4 2017, up from 116 in Q3 2017.
- Funds reported $497M of First Trust NYSE Arca Biotechnology Index Fund stock for Q4 2017, up 11% quarter-over-quarter.
- 30 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q4 2017 and 16 closed out, a net change of +14 holders.
- The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q4 2017 was Churchill Management, an estimated $33.2M added.
- The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q4 2017 was Morgan Stanley, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2017.